Evidence mapPaperPMID 32735150Full record

ReviewAnnals of medicine2020

Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.

Najmeh Ahangari, Mohammad Doosti, Majid Ghayour Mobarhan, Amirhossein Sahebkar, Gordon A Ferns, Alireza Pasdar

Open access · bronzeAbstract readReview
In one paragraph

Review in Annals of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Best of 2025 in prostate cancer and prostatic diseases.Prostate cancer and prostatic diseases · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Najmeh AhangariDepartment of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID 0000-0001-7091-3188
Mohammad DoostiDepartment of Medical Genetics, Next Generation Genetic Polyclinic, Mashhad, Iran.ORCID 0000-0002-2728-8265
Majid Ghayour MobarhanMetabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Amirhossein SahebkarBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Gordon A FernsDivision of Medical Education, Brighton and Sussex Medical School, Brighton, UK.ORCID 0000-0002-0957-8349
Alireza PasdarDepartment of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID 0000-0002-7864-9729
Mashhad University of Medical Sciences · IRBrighton and Sussex Medical School · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statins are the first-line choice in Lipid-lowering therapy to reduce cardiovascular risk. In a continuous attempt to optimise treatment success, there is a need for additional research on genes and related molecular pathways that can determine the efficacy and toxicity of lipid-lowering drugs. Several variations within genes associated with lipid metabolism, including those involved in uptake, distribution and metabolism of statins have been reported. The purpose of this study was to evaluate the effect of genetic variations in the key genes responsible for statins' metabolism and their role in personalised medicine and pharmacogenetic testing (PGx) in patients treated with such drugs. Genetic assessment for specific known SNPs within the most known genes such as

Indexed as

ATP Binding Cassette Transporter, Subfamily G, Member 2Cardiovascular DiseasesCytochrome P-450 CYP3AFeasibility StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesHypercholesterolemiaLiver-Specific Organic Anion Transporter 1Neoplasm ProteinsPharmacogenomic TestingPharmacogenomic VariantsPolymorphism, Single NucleotidePrecision MedicinePrognosisRisk AssessmentABCG2 protein, humanATP Binding Cassette Transporter, Subfamily G, Member 2CYP3A4 protein, humanCytochrome P-450 CYP3AHMGCR protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesLiver-Specific Organic Anion Transporter 1Neoplasm ProteinsSLCO1B1 protein, humanhypercholesterolaemiapersonalised medicineStatins

Identifiers

PMID32735150
PMCPMC7877934
OpenAlexW3046561378

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.